Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Idioma
EN
Communication dans un congrès
Este ítem está publicado en
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, ESMO Congress 2023, 2023-10-20, Madrid. 2023-10, vol. 34, n° supplement 2, p. S1053-S1053
Resumen en inglés
Background: Metastatic osteosarcoma (MOS) has a poor prognosis, and treatment
options are scarce in this rare disease. Large observational studies are needed to
improve patients (pts) care and help designing future ...Leer más >
Background: Metastatic osteosarcoma (MOS) has a poor prognosis, and treatment
options are scarce in this rare disease. Large observational studies are needed to
improve patients (pts) care and help designing future clinical trials.
Methods: Treatment characteristics, outcomes, and prognostic factors of pts > 12
year-old treated for a MOS in 10 French centers from 2008 to 2018 and included in
the prospective database of the French Sarcoma Group were analyzed. The primary
objective was to describe treatment modalities of pts with MOS in a real-life setting,
including systemic treatment (ST) regimen, access to clinical trials (CT) and locoregional
(LR) procedures. Secondary objectives were to assess pts outcome in terms
of time to next treatment (TNT), progression free survival (PFS) and overall survival
(OS) for each line of ST, as well as the impact of CT access and LR procedures on TNT,
PFS and OS in the metastatic setting.
Results: 262 pts with MOS were included, 86 pts were metastatic from diagnosis, 176
pts had a metastatic relapse. Median follow-up was 59.7 months [51.3; 68.4]. Median
age was 26 years (12-85), 48 (18.3%) pts were < 18 year old at metastasis diagnostic.
Main histology was conventional OS (60.3%) and main primary location was inferior
limb (60.3%). 227 (86.6%) pts received ST in the metastatic setting, with a median of 2
lines (IQR 1-3). 101 (38.5%) pts received more than 2 lines. 153 (58.4%) of pts underwent
LR procedure for metastasis, including surgery (49.0%), radiation therapy
(41.8%) or radiological procedures (13.1%); 46 (30.1%) pts had multiple procedures.
Median OS from metastasis diagnosis was 21.5 months [95%CI 18.9-27.0]. Median
TNT was 4.9 months [95%CI 4.3-5.7] for 1rst line, 5.6 months [95%CI 4.6-6.3] for 2nd
line and 3.9 months [95%CI 3.5-5.1] and 2.9 months [95%CI 1.8-4.2] for 3rd and 4rth
lines. 56 (24.7%) pts were included in a CT at least once in the metastatic setting, 29
in 1rst line, 27 in 2nd line and 15 in 3rd line.
Conclusions: This large multicentric observational study details real-world data on
patterns of treatments for pts with MOS in France. Detailed ST regimens used, median
TNT, PFS and OS according to line and ST regimen as well as factors associated with
TNT, PFS and OS will be presented at the meeting.
Legal entity responsible for the study: Institut Bergonie.
Funding: This study received a funding from Bayer and a grant from INCA.
Disclosure: All authors have declared no conflicts of interest.< Leer menos
Centros de investigación